pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$BCABBioAtla, Inc.

$BCAB
San Diego, CA, USupdated 2mo ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Preclinical: 1Phase 2: 4
1Preclinical4Phase 2
Phase 2
evalstotug
Melanoma
Phase 2
mecbotamab vedotin
Non-Small Cell Lung Cancer
Tyrosine-protein kinase receptor UFOTubulin
Phase 2
ozuriftamab vedotin
Head And Neck Cancer
Phase 2
trevotamig
Adenocarcinoma
Preclinical
BA-3142
Head And Neck Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neckcompletedn=42
  • phase2CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCcompletedn=85
  • phase1Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.recruitingn=168
  • phase2CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcomacompletedn=245
  • phase2A Phase 1/2 Study of BA3071 in Patients With Solid Tumorsactive not recruitingn=320
  • phase2CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)completedn=132

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Mar 11, 26grantSHORT JAY M PHD · Chief Executive Officer430,000 sh
  • Mar 10, 26grantSievers Eric · Chief Medical Officer240,000 sh
  • Mar 10, 26grantVasquez Christian · Chief Financial Officer240,000 sh
  • Feb 28, 26tax coverSHORT JAY M PHD · Chief Executive Officer7,728 sh
  • Feb 28, 26tax coverSievers Eric · Chief Medical Officer3,140 sh
  • Feb 28, 26tax coverWALDRON RICHARD A · Former Chief Financial Officer2,729 sh
🐶 Hiring Signal
No open roles indexed yet — view BioAtla, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$BCAB
SEC CIK
0001826892
country
US
source
sec_tickers
top tags
NSCLC5Oncology5Colorectal Cancer3Melanoma3Breast Cancer2
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?